Korea Stock Market Insights

Tag: Delisting

Iljin Display Faces Delisting: What Investors Need to Know
Iljin Display in Crisis: What Should Investors Do?
Iljin Display is on the brink of delisting following the production halt at its Eumseong plant. This article analyzes the current situation and details the crucial factors investors must consider. Read now!
What Happened? – Iljin Display Halts Main Operations
On September 11, 2025, Iljin Display announced a production halt at its Eumseong plant. This constitutes a “major suspension of operations,” triggering a delisting review by the Korea Exchange.
Why Did This Happen? – Deteriorating Fundamentals
Iljin Display was already facing a severe financial crisis as of the first half of 2025. Both the AD division (sapphire wafer) and the DS division (touchscreen panel) experienced declining sales and profitability, coupled with increasing debt and lack of liquidity.
- Sharp decline in sales: Significant drop in AD division sales, decrease in DS division sales
- Operating loss: Both divisions recorded operating losses
- Worsening financial health: Increasing debt ratio, declining current ratio
What Happens Next? – Delisting Possibility and Investment Strategy
The decision of the Corporate Review Committee will determine Iljin Display’s fate. If designated for review, the likelihood of delisting increases significantly. Even if exempted, share price recovery will be challenging without addressing fundamental issues. Short-term price volatility is inevitable, demanding cautious investor approach.
What Should Investors Do? – Proceed with Caution, Monitor Closely
Given the current circumstances, extreme caution is advised for investments in Iljin Display. Monitor the delisting review outcome, the company’s self-rescue plans and management improvement efforts, and macroeconomic changes closely.
Recommendation: Sell or Hold (Investment decisions should be made carefully at your own discretion and responsibility.)
Frequently Asked Questions
Why is Iljin Display facing delisting?
The production halt at Iljin Display’s Eumseong plant is considered a “major suspension of operations,” which is grounds for a delisting review. The company may be delisted depending on the review’s outcome.
Should I sell my Iljin Display shares now?
Iljin Display’s current situation is critical, requiring extreme caution. Experts recommend selling or holding. However, investment decisions should be made carefully at your own discretion and responsibility.
What is the outlook for Iljin Display?
The future outlook hinges on the Corporate Review Committee’s decision and the company’s self-rescue efforts. Even if exempted from review, share price recovery may be difficult without resolving fundamental issues. Conversely, inclusion in the review increases the likelihood of delisting.
What should investors watch out for?
Investors should closely monitor the Corporate Review Committee’s decision, the resumption of production at the Eumseong plant, the company’s self-rescue plans, and fluctuations in exchange rates and interest rates.
09/11/2025
Ilyang Pharmaceutical Accounting Scandal: A Deep Dive and Investor Guide
Ilyang Pharmaceutical’s recent indictment for accounting violations has sent shockwaves through the investment community. This serious event threatens not only the company’s stock price but potentially its very existence. This article provides a comprehensive analysis of the situation, outlining key information investors need and offering crucial guidance for navigating the uncertainty.
What Happened? : Ilyang Pharmaceutical’s Accounting Violations

Ilyang Pharmaceutical faces indictment for accounting violations, and the Korea Exchange is reviewing its eligibility for listing. This situation could lead to trading suspension or even delisting.

Why It Matters: Impact on Investors
- Potential Stock Plunge and Trading Halt: Investors may face difficulty recovering their investments and increased uncertainty.
- Damage to Corporate Image and Credibility: This incident could lead to a long-term decline in investment value.
- Difficulties in Fundraising: The company’s growth potential may be hampered.
What to Do: Investment Strategies and Response Plans
- Monitor Information Closely: Keep track of decisions from the Korea Exchange and company announcements.
- Manage Risk: Consider adjusting stock holdings and implementing stop-loss strategies.
- Invest Cautiously: Carefully monitor the situation before making any investment decisions.
Ilyang’s Future: Analyzing Positive and Negative Factors

Positive Factors: Growth potential of key products like Noltec and Supect, continued R&D investment.

Negative Factors: Loss of trust due to accounting issues, potential worsening of profitability and financial health.

Maintain a balanced perspective and pay close attention to the company’s future actions and further disclosures.
Frequently Asked Questions (FAQ)

Should I sell my Ilyang Pharmaceutical stock now?
The current situation is highly volatile, and investment decisions are up to individual discretion. However, considering risk management, adjusting holdings or implementing stop-loss orders may be prudent.

Is Ilyang Pharmaceutical likely to be delisted?
Delisting is a possibility depending on the Korea Exchange’s review. Staying updated on relevant information is crucial.

What are the details of Ilyang Pharmaceutical’s accounting violations?
The company has been indicted for accounting violations, and the specifics are currently under investigation. Refer to official company announcements and related news for updates.
09/11/2025
Kodako (046070) Delisting Crisis Deepens: Investor’s Guide
Kodako (046070) Delisting Crisis Deepens: An Investor’s Guide
On September 5, 2025, the decision to continue the delisting review for Kodako heightened investor concerns. This article analyzes Kodako’s current situation, future outlook, and investment strategies to provide guidance for investors.
What’s Happening with Kodako (046070)?
The KOSDAQ Market Committee decided on September 5, 2025, to continue the delisting review for Kodako. This is a critical issue that could determine the company’s survival.
Why is Kodako in this situation?
Kodako is currently undergoing rehabilitation proceedings and received a “disclaimer of opinion” in its audit report. This raises serious questions about the company’s financial soundness and transparency. High debt ratios and continued losses further darken the company’s prospects for recovery.
What should investors do?
- Short-term impact: Increased stock price volatility, potential surge in trading volume and sell-off, deterioration of investor sentiment.
- Mid- to long-term impact: Possibility of delisting, restrictions on corporate activities, accelerated deterioration of fundamentals.
Macroeconomic uncertainties could further exacerbate Kodako’s situation.
Investor Action Plan
- Suspend investment: New investments should be carefully considered after confirming the review results and the company’s response.
- Strengthen risk management: Existing investors need to strengthen risk management, considering the possibility of principal loss.
- Obtain additional information: Carefully analyze all disclosed information, including review results and the company’s position.
FAQ
Is Kodako’s delisting confirmed?
Not yet, but the decision to continue the review increases the likelihood of delisting.
What are Kodako’s chances of recovery?
Kodako is undergoing rehabilitation proceedings, but the disclaimer of opinion raises significant uncertainty.
What should investors do?
New investments should be put on hold, and existing investors should strengthen risk management. It’s crucial to closely monitor all disclosed information.
09/05/2025
Winia Aid Submits Improvement Plan: Can it Escape Delisting?

Winia Aid at a Crossroads
Winia Aid has thrown a lifeline in the form of an improvement plan as it teeters on the brink of delisting. Will this be enough to save the company? This article analyzes the background of Winia Aid’s plan, its implications, and the key points investors should focus on to navigate the uncertainty and make informed investment decisions.

What Happened? Winia Aid Submits Improvement Plan

On September 5, 2025, Winia Aid submitted an improvement plan to the Korea Exchange. Having faced a series of crises since 2024, including rehabilitation proceedings, delisting reviews, and formal delisting notices, this submission is a critical event that will determine Winia Aid’s continued listing status.

Why is it Important? A Pivotal Moment for the Company’s Fate

The submission of the improvement plan itself does not directly change the company’s fundamentals. However, as the Korea Exchange’s Corporate Review Committee will decide on the delisting based on this plan, it marks a crucial turning point for Winia Aid’s survival and shareholder value.

What’s Next? Future Outlook and Investment Strategy

The Korea Exchange will decide on delisting or granting an improvement period by October 10, 2025, after reviewing the plan. Continued listing would significantly increase the chances of rehabilitation, while delisting would likely lead to substantial losses for shareholders. The progress of M&A activities and the macroeconomic environment are also key variables that will impact Winia Aid’s future.

What Should Investors Do? Calm Analysis and Prudent Judgment

Investors should carefully consider the specifics of the improvement plan, its feasibility, the Corporate Review Committee’s decision, M&A progress, and macroeconomic changes to make informed investment decisions. It is crucial to manage investment risks through objective analysis and avoid being swayed by short-term stock price fluctuations.

Frequently Asked Questions

What is the significance of Winia Aid’s improvement plan submission?

It’s a rehabilitation plan submitted to the Korea Exchange by Winia Aid, facing delisting, and is a critical step in determining whether it will remain listed.

What is the process after the improvement plan is submitted?

The Korea Exchange will decide on delisting or granting an improvement period by October 10, 2025, after a review by the Corporate Review Committee.

What should investors pay attention to?

Investors need to consider the review results, feasibility of the improvement plan, M&A progress, and the macroeconomic environment to make prudent investment decisions.

09/05/2025
AccessBio Faces Delisting Risk: Delisting Review Extended – What Investors Need to Know
Breaking News: AccessBio’s Future on the Stock Market Uncertain

The Korea Exchange has extended the delisting review period for AccessBio, creating significant uncertainty for investors. This article provides crucial insights into the situation and offers guidance for investors.
What Happened?: Delisting Review Extended

The Korea Exchange extended AccessBio’s delisting review period to September 26, 2025. This extension raises serious questions about the company’s ability to remain listed on the exchange.

Why?: Increased Uncertainty Surrounding Delisting

The extension suggests that the Korea Exchange requires more information to assess AccessBio’s eligibility for continued listing. This uncertainty adds to investor concerns and could lead to increased stock price volatility.

What’s Next?: Potential Risks and Opportunities
- Worst-Case Scenario: Delisting could result in significant losses for investors.
- Continued Uncertainty: Stock price volatility is likely to persist throughout the review period.
- Potential Opportunity: If AccessBio is not delisted, the resolution of uncertainty could lead to a rebound in stock price, although the probability is low.
Investor Action Plan

Investors should closely monitor the Korea Exchange’s final decision and any related announcements. Maintaining a rational approach during this period of uncertainty is crucial. Consider establishing a stop-loss strategy to mitigate potential losses.
What is AccessBio’s delisting review?

The delisting review is a process by which the Korea Exchange evaluates a company’s suitability for continued listing. Factors such as financial health and management transparency are considered.

When will the review results be announced?

The review period has been extended to September 26, 2025, but further extensions are possible.

What should investors do?

Investors should closely monitor announcements and exercise caution. Consider a stop-loss strategy to manage risk.
09/05/2025
SD Biotech (217480) Asset Sale: A Lifeline or a Last Resort? Analysis and Investment Strategy
SD Biotech’s Asset Sale: A Glimmer of Hope or a Desperate Gamble?
Facing delisting, SD Biotech has sold assets worth KRW 15.3 billion. Will this move be enough to change the company’s fate? While providing short-term liquidity, it may not address the underlying financial issues and delisting risk. This article offers a comprehensive analysis of SD Biotech’s asset sale and provides clear action plans for investors.
1. What Happened? SD Biotech’s Asset Sale

SD Biotech announced on September 5, 2025, the sale of land, buildings, and machinery located in Eumseong, Chungbuk, to USPharmatech Korea for KRW 15.3 billion. The stated purpose is to secure operating funds and improve the financial structure. The assets represent 25.22% of the company’s total assets.

2. Why the Asset Sale? SD Biotech’s Crisis

SD Biotech is grappling with continuous operating losses, accumulated deficit, and the looming threat of delisting. Sales in the first half of 2025 decreased by 14.5% year-on-year, and high SG&A expenses continue to erode profitability. The Korea Exchange has voted to delist the company. This desperate situation suggests the asset sale is a move to secure short-term liquidity.

3. Impact of the Asset Sale
- Positive Effects (Short-term):
  
  KRW 15.3 billion cash inflow offers temporary relief
  
  Potential for temporary improvement in financial structure
- Negative Effects and Risks:
  
  Underlying profitability issues remain unresolved
  
  Delisting risk still present
  
  Potential disruption to future operations due to sale of production facilities
  
  Concerns about negative impact on investor sentiment
4. What Should Investors Do?

Investing in SD Biotech at this point requires extreme caution. The asset sale appears to be a temporary fix, unlikely to reverse the company’s fortunes. Before making any investment decisions, carefully consider the following:
- The Korea Exchange’s final decision on delisting
- The company’s plans for utilizing the proceeds and evidence of actual financial improvement
- The company’s future business plans and strategies for enhancing competitiveness
Frequently Asked Questions (FAQ)

What’s the positive side of SD Biotech’s asset sale?

It provides short-term liquidity, offering temporary relief from immediate financial crisis and preventing further deterioration.

Why is investing in SD Biotech still risky despite the asset sale?

The asset sale is a short-term solution and doesn’t address the fundamental problems of operating losses, accumulated deficit, and the risk of delisting. It may even weaken the company’s long-term growth prospects.

What should investors pay attention to?

Investors should closely monitor the Korea Exchange’s final decision on delisting, how the company plans to use the proceeds, and the company’s future business plans. Critically evaluate the feasibility of the business plan and the competitiveness enhancement strategy.
09/05/2025
NKMAX Trading Halt Extended: Delisting Risk Intensifies? Urgent Investor Check
NKMAX Trading Halt Extended: What Should Investors Do Now?

Investor anxiety is rising as NKMAX’s delisting review period has been extended. Despite undergoing rehabilitation proceedings, the increased possibility of delisting has investors on high alert. This article analyzes NKMAX’s current situation and provides investment strategies, focusing on the significance of the final decision on September 24th.
1. What Happened? Analysis of NKMAX’s Trading Halt Extension

The Korea Exchange announced on September 3, 2025, a 15-business-day extension of the review period for determining whether NKMAX is subject to delisting review, until September 24th. This also means an extension of NKMAX’s trading halt.

2. Why Did This Happen? Background and Issues

NKMAX received approval for its rehabilitation plan in June 2025 and has been making efforts to normalize management, including changing its largest shareholder. However, there are still challenges to overcome, such as severe capital impairment and continuous operating losses. These factors influence the decision regarding delisting review.
- Positive Factors: Achieving rehabilitation milestones, change of largest shareholder, growth potential of the immune cell therapy market
- Negative Factors: Severe capital impairment, continuous operating losses, delisting uncertainty
3. What’s Next? Future Outlook and Scenarios

The extension of the review period can be interpreted as increasing the likelihood of delisting. NKMAX’s stock price is expected to be highly volatile depending on the final decision on September 24th. In the worst case, it could lead to delisting, causing significant losses to investors.

4. What Should Investors Do? Action Plan

Currently, investing in NKMAX carries very high risks. It is advisable to hold off on investments and observe the situation until the announcement on September 24th. If you have already invested, you should prepare for the possibility of delisting.
- Suspend investment and wait
- Consider the worst-case delisting scenario
- Strengthen information monitoring
Frequently Asked Questions

When will the results of NKMAX’s delisting review be announced?

It is scheduled to be announced on September 24, 2025.

What is the probability of NKMAX being delisted?

While the extension of the review period is interpreted as increasing the likelihood of delisting, nothing is confirmed. We must wait for the announcement on September 24th.

Should I sell NKMAX stock now?

Currently, trading is halted, so selling is not possible. The decision to sell should be made after the results are announced on September 24th, when trading resumes. Investment decisions should be made carefully, and consulting with a professional is recommended.
09/03/2025
CCS (066790) Lawsuit Withdrawal: Calm Before the Storm? Investor Alert!
Are you following the news of CCS (066790)’s lawsuit withdrawal? While this withdrawal might seem positive in the short term, it doesn’t resolve the fundamental problems facing CCS. It could be the calm before the storm. This article provides a cold, hard look at CCS’s current situation and highlights crucial points for investors to consider.
What Happened? The Story Behind CCS’s Lawsuit Withdrawal
On September 3, 2025, CCS announced that the plaintiff in the ‘indirect coercion application (2025타기1054)’ case had fully withdrawn the lawsuit. This case, which was being heard at the Chungju Branch of the Cheongju District Court, was withdrawn at the request of the creditor.
Why Does the Withdrawal Matter?
The withdrawal could be interpreted as a positive sign, reducing some uncertainty surrounding CCS. However, the fundamental issues plaguing CCS—management disputes, violation of broadcasting laws, dishonest disclosures, and delisting risks—remain unresolved. Therefore, it’s unlikely that this withdrawal alone will improve CCS’s fundamentals.
What’s Next for CCS?
CCS’s future stock price hinges on resolving the management dispute, addressing the delisting issue, recovering competitiveness in its core business, and improving profitability. As of the 2025 semi-annual report, CCS’s fundamentals are highly unstable. Negative factors such as declining sales, widening operating losses, and financial risks are piling up. Worsening macroeconomic indicators could also negatively impact CCS.
Investor Action Plan
- Careful Investment Consideration: Investing in CCS requires extreme caution. Don’t be fooled by short-term stock fluctuations; thoroughly analyze the company’s fundamentals from a long-term perspective.
- Thorough Risk Management: Always be mindful of potential losses when investing, and only invest what you can afford to lose. Strategies like diversified investment are essential to minimize risk.
- Continuous Information Gathering: Continuously monitor CCS-related disclosures, news, and analysis reports to gather the information necessary for investment decisions.
FAQ
Is CCS’s lawsuit withdrawal positive for the stock price?
It might have a positive impact in the short term, but the long-term stock price depends on whether CCS’s fundamentals improve.
Is there a possibility of CCS being delisted?
The risk of delisting still exists due to accumulated dishonest disclosures. Investors should be aware of this risk.
Should I invest in CCS?
CCS currently carries very high risk. Investment decisions should be made with extreme caution.
09/03/2025
Exion Group Trading Resumes: Rebound or Risk? Investment Strategy Analysis
Exion Group’s trading has resumed after being removed from the list of companies under review for delisting. Was this decision a sign of a true rebound for Exion Group, which was once on the verge of delisting? This article analyzes the background and implications of Exion Group’s trading resumption, its financial status, and key strategies for investors. Be sure to review this essential information before making any investment decisions!
What Happened?
Exion Group’s trading was halted on August 14, 2025, due to reasons related to delisting review. However, with the submission of amended reports on August 29, these reasons were resolved, and trading will resume on September 2.
Why Did This Happen?
This was due to the discovery of errors in revenue recognition in the 2025 semi-annual report, necessitating amended disclosures. This process led to revisions in the financial statements, notably a decrease of 66 million won in consolidated net income.
What Are the Implications?
- Short-Term Impact: Trading resumption is positive for investor sentiment and liquidity. However, there is a possibility of increased stock price volatility in the initial stages.
- Long-Term Impact: Enhanced transparency of financial information is positive. However, high debt-to-equity ratio and uncertainties surrounding new businesses remain risk factors.
- Market Impact: Provides a positive example for similar companies. However, there’s a possibility of increased competition due to business diversification.
Investor Action Plan
While the resumption of trading is positive, uncertainties persist regarding Exion Group’s fundamentals. Investors should consider the following:
- Check the plan to strengthen financial soundness
- Evaluate the performance and growth potential of new businesses
- Confirm improvements in internal control systems
- Review strategies to respond to macroeconomic variables and market volatility
Investors should make prudent investment decisions by closely monitoring the company’s earnings announcements, progress of new businesses, etc.
FAQ
When will Exion Group’s trading resume?
Trading will resume on September 2, 2025.
What is the outlook for the stock price after trading resumes?
High volatility is expected in the short term, and the long-term stock price will depend on improvements in financial soundness and the performance of new businesses.
What are the key considerations for investors?
Investments should be made prudently, considering the high debt-to-equity ratio and uncertainties surrounding new businesses. It is crucial to carefully analyze the company’s disclosed information and market conditions.
09/01/2025
Mirae Asset Dream SPAC 1 Faces Delisting Risk: Urgent Advice for Investors
Mirae Asset Dream SPAC 1 Faces Delisting Risk: Urgent Advice for Investors

Mirae Asset Dream SPAC 1 is facing a potential delisting crisis. The company must submit its merger preliminary review application by September 8, 2025, or risk being designated as a 관리종목 (managed stock), a designation that could ultimately lead to delisting. This article provides a crucial analysis of the situation, future outlook, and urgent advice for investors.
What Happened?

Mirae Asset Dream SPAC 1 is required to submit a merger preliminary review application by September 8, 2025. Failure to meet this deadline will result in the company being designated as a 관리종목 (managed stock) on September 9, 2025. If the situation isn’t rectified within one month, the company faces potential delisting from the exchange.

Why is this happening?

As a Special Purpose Acquisition Company (SPAC), Mirae Asset Dream SPAC 1’s sole purpose is to merge with a private company within a specific timeframe. The company has yet to identify a suitable merger target, putting it at risk of delisting. While they are considering targets in renewable energy, biopharmaceuticals, and IT convergence systems, no concrete merger process has begun.

What’s Next?

In the short term, the likelihood of being designated a 관리종목 is high, which will likely negatively impact investor sentiment and put downward pressure on the stock price. The medium to long-term outlook hinges on whether the company can submit the preliminary review application and successfully complete a merger. While a successful merger would resolve the crisis, the current uncertainty raises the possibility of delisting.

What Should Investors Do?
- Monitor the Application Submission: Closely monitor whether the company submits the preliminary review application by the September 8th deadline.
- If Submitted: Thoroughly analyze the proposed merger target before making any investment decisions.
- If Not Submitted: Consider strategies to recover your investment or minimize potential losses.
- Invest with Caution: Understand the inherent risks associated with SPAC investments, particularly the uncertainty surrounding mergers.
Frequently Asked Questions

What is a 관리종목 (managed stock)?

A 관리종목 is a designation given by the Korea Exchange to companies facing a high risk of delisting. This designation is intended to protect investors and comes with restrictions such as reduced trading volume and limited access to information.

What is a SPAC?

A SPAC (Special Purpose Acquisition Company) is a shell company created solely for the purpose of merging with or acquiring a private company and taking it public.

Why is Mirae Asset Dream SPAC 1 facing delisting risks?

The company is nearing its deadline to merge with a target company and has yet to identify a suitable candidate. Failure to complete a merger within the timeframe could lead to delisting.
09/01/2025